References
- 115th Congress. H.R.6 SUPPORT for Patients and Communities Act, Section 3202. Washington (DC): 115th Congress; 2018. Available from: https://www.congress.gov/bill/115th-congress/house-bill/6/text#toc-HE7D6B79AFB0447CD9D2F6F189A1586FE . Accessed August 10, 2022.
- Andrilla, C. H. A., Moore, T. E., Patterson, D. G., & Larson, E. H. (2019). Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. The Journal of Rural Health, 35(1), 108–112. https://doi.org/10.1111/jrh.12307
- Bhatraju, E. P., Grossman, E., Tofighi, B., McNeely, J., DiRocco, D., Flannery, M., Garment, A., Goldfeld, K., Gourevitch, M. N., & Lee, J. D. (2017). Public sector low threshold office-based buprenorphine treatment: Outcomes at year 7. Addiction Science & Clinical Practice, 12(1), 1–10. https://doi.org/10.1186/s13722-017-0072-2
- Buchheit, B. M., Wheelock, H., Lee, A., Brandt, K., & Gregg, J. (2021). Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects. Journal of Substance Abuse Treatment, 131, 108444. https://doi.org/10.1016/j.jsat.2021.108444
- Eibl, J. K., Gauthier, G., Pellegrini, D., Daiter, J., Varenbut, M., Hogenbirk, J. C., & Marsh, D. C. (2017). The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug and alcohol dependence, 176, 133–138. https://doi.org/10.1016/j.drugalcdep.2017.01.048
- HHS: Office for Civil Rights. (2021). Notification of enforcement discretion for telehealth remote communications during the COVID-19 nationwide public health emergency. HHS.gov. https://www.hhs.gov/hipaa/for-professionals/special-topics/emergency-preparedness/notification-enforcement-discretion-telehealth
- Jakubowski, A., & Fox, A. (2020). Defining low-threshold buprenorphine treatment. Journal of Addiction Medicine, 14(2), 95. https://doi.org/10.1097/ADM.0000000000000555
- Krawczyk, N., Buresh, M., Gordon, M. S., Blue, T. R., Fingerhood, M. I., & Agus, D. (2019). Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap. Journal of Substance Abuse Treatment, 103, 1–8. https://doi.org/10.1016/j.jsat.2019.05.002
- Levander, X. A., Wheelock, H., Pope, J., Lee, A., Hartmann, K., Abuelkhair, S., Gregg, J. L., & Buchheit, B. M. (2021). Low-threshold buprenorphine via community partnerships and telemedicine—case reports of expanding access to addiction treatment during COVID-19. Journal of Addiction Medicine, 16(1), e56–58. https://doi.org/10.1097/ADM.0000000000000811
- Tofighi, B., Leonard, N., Greco, P., Hadavand, A., Acosta, M. C., & Lee, J. D. (2019). Technology use patterns among patients enrolled in inpatient detoxification treatment. Journal of Addiction Medicine, 13(4), 279. https://doi.org/10.1097/ADM.0000000000000494
- Tofighi, B., McNeely, J., Walzer, D., Fansiwala, K., Demner, A., Chaudhury, C. S., Subudhi, I., Schatz, D., Reed, T., & Krawczyk, N. (2021). A telemedicine buprenorphine clinic to serve New York City: Initial evaluation of the NYC public hospital system’s initiative to expand treatment access during the COVID-19 pandemic. Journal of Addiction Medicine, 16(1), e40–43. https://doi.org/10.1097/ADM.0000000000000809
- Wang, L., Weiss, J., Ryan, E. B., Waldman, J., Rubin, S., & Griffin, J. L. (2021). Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic. Journal of Substance Abuse Treatment, 124, 108272. https://doi.org/10.1016/j.jsat.2020.108272